Patidegib

Drug Profile

Patidegib

Alternative Names: FIN-5; IPI-926; Patidegib topical gel - PellePharm; Saridegib

Latest Information Update: 27 Feb 2017

Price : $50

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Infinity Pharmaceuticals; PellePharm
  • Class Antineoplastics; Small molecules; Veratrum alkaloids
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chondrosarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Basal cell cancer; Basal cell nevus syndrome
  • Discontinued Chondrosarcoma; Head and neck cancer; Myelofibrosis; Pancreatic cancer

Most Recent Events

  • 08 Dec 2016 Patidegib licensed to PellePharm before December 2016
  • 01 Oct 2016 Phase-II clinical trials in Basal cell cancer (First-line therapy) in USA (Topical) (NCT02828111)
  • 18 Jun 2012 Discontinued - Phase-II for Chondrosarcoma in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top